BL 3730

Drug Profile

BL 3730

Alternative Names: BL-3730

Latest Information Update: 01 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dainippon Pharmaceutical
  • Class
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Multiple organ failure; Reperfusion injury; Respiratory distress syndrome

Most Recent Events

  • 30 Apr 2001 Preclinical development for Multiple organ failure in Japan (Unknown route)
  • 30 Apr 2001 Preclinical development for Reperfusion injury in Japan (Unknown route)
  • 30 Apr 2001 Preclinical development for Respiratory distress syndrome in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top